Answers are grounded in this paper and cite their sources.
Case report reveals ocular surface toxicity in a melanoma patient undergoing targeted therapy, suggesting the need for careful management.
We report the case of a patient with metastatic foot melanoma enrolled in a clinical trial of the anti‐RAS agent RMC‐6236 who developed chronic bilateral corneal epithelial defects and thinning, likely secondary to the systemic effects of targeted therapy. This case highlights the ocular surface toxicity associated with systemic anticancer therapies affecting rapidly dividing cells and the overall importance of multidisciplinary medical management of these systemic therapeutics.
No takes yet. Share an insight, caveat, or question.
Huynh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: